MétaCan
Menu
Back to cohort

S98 Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis (IPF) under pirfenidone treatment

2016· article· en· W2568011902 on OpenAlexaff
Michael Kreuter, Paolo Spagnolo, Wim Wuyts, Elisabetta Renzoni, Dirk Koschel, Francesco Bonella, Toby M. Maher, Martin Kolb, Derek Weycker, Klaus-Uwe Kirchgässler, Ulrich Costabel

Bibliographic record

VenueThorax · 2016
Typearticle
Languageen
FieldMedicine
TopicInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Canadian institutionsMcMaster University
Fundersnot available
KeywordsMedicinePirfenidoneInternal medicineVital capacityIdiopathic pulmonary fibrosisPulmonary function testingAdverse effectGastroenterologyPlaceboPost-hoc analysisDiffusing capacityPathologyLung

Abstract

fetched live from OpenAlex

<h3>Introduction</h3> On the basis of retrospective and post-hoc analyses the current IPF guideline suggests the use of anti-acid therapy (AAT, i.e., proton pump inhibitors and H2-blockers) as a treatment option in patients with IPF. While recent post-hoc analyses do not support a protective effect of AAT on IPF progression in patients receiving placebo, the impact of AAT on disease progression in patients treated with pirfenidone is unknown. <h3>Methods</h3> Patients with IPF randomised to pirfenidone in 3 trials (CAPACITY studies 004 and 006, and ASCEND) were included. Changes in pulmonary function, exercise tolerance, survival, hospitalizations, and adverse events (AEs) over 52 weeks were analysed for all subjects, based on AAT status at baseline, by bivariate and multivariate analyses. Disease progression was defined as an absolute decrease of forced vital capacity (FVC) ≥10% predicted, a decrease of ≥50 m in the 6-minute walk distance (6MWD) or death. <h3>Results</h3> Of 623 patients, 44% received AAT. Patient characteristics were comparable between groups with the exception of gastrointestinal (GI) comorbidities. In bivariate analyses, there were no significant differences at 52 weeks in disease progression (AAT vs non-AAT: 24.9% vs 30.6%; <i>P</i> = 0.12), all-cause or IPF-related mortality (2.9% vs 4.0%; <i>P</i> = 0.47 and 1.1% vs 2.0%; <i>P</i> = 0.37, respectively), all-cause hospitalisation (16.1% vs. 18.3%, <i>P</i> = 0.48) or observed mean FVC decline (−2.7% vs −3.1%, <i>P</i> = 0.44). Relative but not absolute FVC decline ≥10% was slightly in favour of AAT (15% vs 22%; <i>P</i> = 0.03). In multivariate analyses, hazard ratios across study outcomes ranged from 0.3–0.9 for AAT (vs. non-AAT), although differences were not statistically significant (including relative FVC decline ≥10%). AEs were generally similar between groups; however, severe GI AEs (3.7% vs. 0.9%, <i>P</i> = 0.015) and severe pulmonary infections (3.7% vs. 1.1%, <i>P</i> = 0.035) were more frequent in AAT users. <h3>Conclusion</h3> In this post-hoc analysis of three randomized-controlled trials, there was no clear evidence of benefit of the combination of AAT and pirfenidone compared to pirfenidone alone. However, AAT use appeared to increase the risk of severe GI and infectious AEs. AAT should be prospectively assessed in a randomised controlled trial before being considered as a specific treatment for IPF.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.217
Threshold uncertainty score0.598

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.258
Teacher spread0.245 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueThoraxSame topicInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisFrench-language works237,207